Phase 2 Head and Neck Cancer Trial, Recruiting NCT05674396 Sponsor: M.D. Anderson Cancer Center Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT05674396
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who are willing to give their formal agreement to take part in the study
  • People whose cancer has been confirmed by laboratory testing to be squamous cell carcinoma (a specific type of cancer that develops from certain skin-like cells)
  • People whose cancer started in the head or neck area, including the mouth, throat, voice box, salivary glands, skin of the head and neck, or in cases where the original cancer site is unknown
  • People whose medical team, after a full review involving a radiation specialist, surgeon, and a multidisciplinary tumour board, has determined that treatment aimed at curing the cancer is not suitable
  • People who have previously had radiation, surgery, or other cancer treatments — as long as the treating doctor considers further radiation to be appropriate
  • People whose cancer has spread to other parts of the body (metastatic disease)

Who may not be able to join:

  • People for whom radiation therapy is medically unsafe or not recommended
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jay Reddy, MD,PHD, M.D. Anderson Cancer Center

Phone: (832) 750-2924

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
30 June 2023
Est. completion
30 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

M. D. Anderson Symptom Inventory - Head & Neck (MDASI-HN) Questionnaires

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov